All In Biotech

Drug Trial Radar · NCT06432166

2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients

2-Hydroxybenzylamine (2-HOBA) Phase 1b/2a Proof-of Concept, Dose-Finding, Biomarker Study in Early Alzheimer's Patients

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Dec 30, 2028

Study completion Jun 30, 2029

Sponsor

Lead sponsor
MTI Biotech IncIndustry
Sponsor type
Industry
Collaborators
Vanderbilt University Medical Center
First posted
May 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Investigators propose a phase 1b/2a, randomized, double-blind, placebo-controlled, parallel group dose finding and biomarker study to evaluate the safety, tolerability, and biomarker activity of 2-HOBA in 48 MCI/AD participants. Participants will be randomized 1:1:1:1 to receive 250 mg BID, 250 and 500 mg 2-HOBA acetate TID or placebo for 12 weeks. Blood and cerebral spinal fluid (CSF) will be collected to measure markers of protein modification by dicarbonyls (IsoLGs- \& MDA), pTau-181, YKL-40, and NF-L.

Conditions

  • Alzheimer Disease
  • Mild Cognitive Impairment

Interventions

  • 2-hydroxybenzylamine acetateDrug

    2-hydroxybenzylamine acetate (2-HOBA) is taken daily for 12 weeks

  • PlaceboOther

    Placebo taken three times per day for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety/Tolerability (adverse events)Time frame: Baseline to week 12
  2. Change in dicarbonyl protein adductsTime frame: Baseline to week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Center for Cognitive Medicine, Vanderbilt University Medical Center

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.